Global Meloxicam Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Meloxicam Market Size

• The global meloxicam market size was valued at USD 7.39 billion in 2024 and is expected to reach USD 10.91 billion by 2032, at a CAGR of 5.00% during the forecast period
• The market growth is largely fueled by the increasing prevalence of arthritis and musculoskeletal disorders worldwide, along with the rising geriatric population that demands effective anti-inflammatory and pain management therapies
• Furthermore, growing adoption of generic formulations, coupled with expanding accessibility through retail and online pharmacies, is establishing meloxicam as a widely preferred nonsteroidal anti-inflammatory drug (NSAID). These converging factors are accelerating its consumption rate, thereby significantly boosting the industry’s growth

Meloxicam Market Analysis

• Meloxicam, a widely used nonsteroidal anti-inflammatory drug (NSAID), is increasingly vital for managing arthritis, osteoarthritis, and other musculoskeletal disorders in both outpatient and hospital settings due to its efficacy in reducing inflammation and pain with fewer gastrointestinal side effects compared to traditional NSAIDs
• The escalating demand for meloxicam is primarily fueled by the rising prevalence of chronic inflammatory conditions, an aging global population, and growing awareness of pain management therapies among patients and healthcare providers
• North America dominated the meloxicam market with the largest revenue share of 39% in 2024, characterized by high healthcare expenditure, widespread prescription drug usage, and a strong presence of key pharmaceutical manufacturers, with the U.S. experiencing substantial growth in both generic and branded meloxicam formulations, driven by ongoing clinical research and adoption in chronic pain management protocols
• Asia-Pacific is expected to be the fastest-growing region in the meloxicam market during the forecast period due to increasing healthcare access, expanding pharmaceutical manufacturing capabilities, and rising prevalence of arthritis and related disorders
• Osteoarthritis segment dominated the meloxicam market with a share of 45.7% in 2024, driven by the high prevalence of osteoarthritis worldwide and growing demand for effective long-term pain management solutions

Report Scope and Meloxicam Market Segmentation 

Meloxicam Market Trends

Rising Preference for Targeted Anti-Inflammatory Therapies

• A significant and accelerating trend in the global meloxicam market is the growing adoption of targeted NSAID therapies that minimize gastrointestinal side effects while maintaining effective pain relief, enhancing patient compliance and therapeutic outcomes
  • For instance, modified-release meloxicam tablets allow controlled dosing over extended periods, improving convenience for patients with chronic arthritis or osteoarthritis conditions. Similarly, oral dispersible formulations are gaining traction among elderly patients who have difficulty swallowing conventional tablets
• Advances in formulation technologies enable meloxicam to be combined with other analgesic or disease-modifying drugs, creating dual-action therapies that reduce inflammation and pain simultaneously. For instance, certain fixed-dose combination products pair meloxicam with gastroprotective agents to improve tolerability
• Healthcare providers are increasingly recommending meloxicam over other traditional NSAIDs due to its improved safety profile, particularly in geriatric populations with comorbidities. Through enhanced prescription guidance, patients receive optimized dosing tailored to their conditions, improving adherence and satisfaction
• Expansion of digital health platforms and telemedicine services is facilitating easier prescription and monitoring of meloxicam therapy, particularly for chronic pain patients in remote areas. For instance, digital prescription platforms allow physicians to adjust doses based on patient-reported outcomes
• This trend towards safer, patient-friendly, and targeted anti-inflammatory therapies is fundamentally reshaping physician prescribing behavior. Consequently, pharmaceutical companies are investing in novel meloxicam formulations with sustained-release and combination therapies to meet evolving market needs
• The demand for meloxicam formulations with enhanced safety and convenience features is growing rapidly across both developed and emerging markets, as patients and healthcare providers increasingly prioritize tolerability and long-term management of chronic pain conditions

Meloxicam Market Dynamics

Driver

Increasing Prevalence of Arthritis and Musculoskeletal Disorders

• The rising incidence of osteoarthritis, rheumatoid arthritis, and other musculoskeletal disorders worldwide is a significant driver for the heightened demand for meloxicam
  • For instance, according to WHO reports in 2024, arthritis affects millions globally, creating a strong need for effective NSAIDs such as meloxicam to manage chronic pain and inflammation
• Healthcare providers increasingly prefer prescribing meloxicam due to its efficacy and lower gastrointestinal risk compared to traditional NSAIDs, enhancing adoption rates in both outpatient and hospital settings
• Growing geriatric populations with chronic pain conditions further contribute to market growth, as elderly patients require long-term, tolerable anti-inflammatory medications
• Increased awareness of pain management therapies and accessibility through retail and online pharmacies are making meloxicam a preferred treatment option for chronic inflammatory conditions
• Rising investment by pharmaceutical companies in research and development for improved meloxicam formulations and delivery methods is expected to drive market growth. For instance, development of sustained-release and parenteral forms is enhancing therapeutic convenience and adherence
• Increasing government initiatives and healthcare programs supporting chronic disease management, especially in emerging markets, are encouraging wider adoption of meloxicam. For instance, public health campaigns promoting safe and effective arthritis management are boosting demand

Restraint/Challenge

Adverse Effects and Regulatory Compliance Concerns

• Concerns regarding potential side effects of long-term meloxicam use, including cardiovascular and renal risks, pose a significant challenge to broader market penetration
  • For instance, reports of gastrointestinal bleeding or renal complications have made some physicians cautious in prescribing meloxicam to high-risk patients
• Ensuring compliance with stringent regulatory standards across different regions is crucial, as delays in approvals or recalls can impact market growth and company reputation
• In addition, the availability of alternative NSAIDs and analgesics at lower costs can limit meloxicam adoption in price-sensitive markets, particularly in emerging economies
• Addressing these challenges through physician education, patient awareness programs, and development of safer formulations will be vital for sustained market growth
• Market fragmentation and competition from local generic manufacturers can reduce profit margins for branded meloxicam products, posing challenges for established pharmaceutical players. For instance, emerging regional players often offer lower-cost generics with similar efficacy
• Limited patient adherence due to chronic dosing requirements may hinder consistent market growth, particularly in populations with low health literacy or limited access to healthcare support. For instance, elderly patients may miss doses or discontinue therapy prematurely without proper monitoring

Meloxicam Market Scope

The market is segmented on the basis of diseases, drug type, population type, dosage, dose strength, end-users, and distribution channel.

• By Diseases

On the basis of disease, the meloxicam market is segmented into osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, and others. The osteoarthritis segment dominated the market in 2024, holding the largest revenue share of 45.7%, driven by the high prevalence of osteoarthritis worldwide and growing demand for effective long-term pain management solutions. Osteoarthritis patients often require consistent NSAID therapy, making meloxicam a preferred choice due to its once-daily dosing, improved safety profile, and lower gastrointestinal side effects. Physicians increasingly prescribe meloxicam for elderly patients with chronic joint inflammation, further bolstering its dominance. The segment also benefits from the availability of multiple formulations and strengths, allowing for tailored dosing based on patient needs. In addition, awareness programs and arthritis support initiatives are encouraging more patients to seek timely treatment, increasing overall consumption. The segment’s growth is reinforced by increasing government initiatives promoting chronic disease management in developed regions.

The rheumatoid arthritis segment is expected to witness the fastest growth from 2025 to 2032, driven by rising awareness and early diagnosis of autoimmune conditions in emerging markets. Rheumatoid arthritis patients require potent anti-inflammatory therapy to manage disease progression and pain, and meloxicam’s efficacy and tolerability make it a preferred NSAID. The increasing adoption of combination therapies with DMARDs (disease-modifying antirheumatic drugs) also boosts market demand. Expansion of healthcare infrastructure, insurance coverage, and access to specialist clinics further supports rapid segment growth. For instance, improved access to rheumatologists in Asia-Pacific and Latin America has accelerated prescription rates of meloxicam. Patient adherence programs and physician training initiatives also contribute to sustained growth in this segment.

• By Drug Type

On the basis of drug type, the market is segmented into generic and branded formulations. The generic segment dominated the market in 2024, accounting for the largest revenue share due to its cost-effectiveness and wider accessibility, especially in price-sensitive regions. Generic meloxicam offers the same therapeutic benefits as branded products but at a lower cost, making it the preferred choice for long-term arthritis management. High adoption rates in hospitals, retail pharmacies, and online channels further drive generic sales. Physicians often recommend generics to improve patient adherence without compromising efficacy. The segment benefits from growing approvals of generic versions by regulatory authorities across multiple countries. Patient preference for affordable therapy and increasing government support for generic drugs strengthen this segment’s position.

The branded segment is expected to witness the fastest growth from 2025 to 2032, driven by strong marketing, physician trust, and perceived quality assurance. Branded meloxicam products often introduce novel formulations, such as sustained-release or combination therapies, which appeal to patients and healthcare providers. Expansion into emerging markets with awareness campaigns and partnerships with hospitals and specialty clinics further fuels growth. Brand loyalty and consistent regulatory compliance also support premium pricing strategies. Increasing investment in R&D by pharmaceutical companies for innovative branded formulations further accelerates growth in this segment.

• By Population Type

On the basis of population type, the market is segmented into adult and children. The adult segment dominated the market in 2024, with the largest revenue share due to the high incidence of osteoarthritis, rheumatoid arthritis, and musculoskeletal disorders among adults. Adults require long-term anti-inflammatory therapy, and meloxicam’s efficacy, safety, and once-daily dosing make it highly preferred. The segment benefits from greater healthcare access, prescription coverage, and patient adherence programs. Healthcare providers actively promote NSAIDs such as meloxicam for adults with chronic pain conditions. In addition, lifestyle-related increases in arthritis prevalence contribute to sustained demand. The adult population’s ability to afford and access treatment further strengthens the dominance of this segment.

The children segment is expected to witness the fastest growth from 2025 to 2032, fueled by increasing diagnosis of juvenile rheumatoid arthritis and improved pediatric healthcare infrastructure. Pediatric formulations, including low-dose oral tablets and dispersible options, are gaining traction. Awareness campaigns by healthcare providers and NGOs about early arthritis management in children are also contributing to growth. Rising clinical research on safe NSAID use in children supports this trend. Increasing government and insurance support for pediatric chronic care further boosts adoption in this segment.

• By Dosage

On the basis of dosage, the market is segmented into oral, parenteral, transdermal, and others. The oral segment dominated the market in 2024, capturing the largest revenue share due to ease of administration, patient compliance, and wide availability in tablets and dispersible forms. Oral meloxicam is commonly prescribed for chronic conditions and is preferred in outpatient and home healthcare settings. Its once-daily dosing simplifies therapy for elderly and adult patients, ensuring adherence. Physicians favor oral forms for long-term therapy due to predictable pharmacokinetics and convenience. The segment also benefits from a robust supply chain through pharmacies and online channels. Increasing patient preference for non-invasive medication further strengthens the oral segment’s dominance.

The parenteral segment is expected to witness the fastest growth from 2025 to 2032, driven by hospital and specialty clinic demand for injectable meloxicam in acute pain management and post-surgical care. Parenteral formulations provide rapid onset of action and are essential for patients unable to take oral medications. Expansion of hospital infrastructure and increased surgical procedures globally support segment growth. For instance, injectable meloxicam is widely adopted in orthopedic and postoperative pain management protocols. Increasing awareness among healthcare providers regarding rapid pain relief options further accelerates adoption.

• By Dose Strength

On the basis of dose strength, the market is segmented into 7.5mg, 15mg, and others. The 7.5mg segment dominated the market in 2024, holding the largest revenue share due to its safer profile, particularly for elderly patients or those with comorbidities. Lower doses reduce gastrointestinal and renal risks while maintaining therapeutic efficacy for chronic pain management. Physicians often initiate therapy at 7.5mg before titrating to higher doses if needed. The segment benefits from high prescription volumes and widespread availability across retail and hospital pharmacies. Patient preference for lower doses with fewer side effects also drives adoption. Clinical guidelines recommending cautious dosing in elderly populations further strengthen this segment.

The 15mg segment is expected to witness the fastest growth from 2025 to 2032, fueled by demand for higher potency in patients with severe inflammation or inadequate response to lower doses. Higher-strength tablets are also increasingly prescribed in specialty clinics and hospital settings for acute arthritis flares. Clinical guidelines recommending flexible dosing options support segment growth. Expansion of generic and branded 15mg formulations across emerging markets further accelerates adoption. Increasing awareness of dosage optimization by physicians enhances patient outcomes and supports growth.

• By End-Users

On the basis of end-users, the market is segmented into hospitals, specialty clinics, home healthcare, and others. The hospitals segment dominated the market in 2024, holding the largest revenue share due to high patient inflow, chronic pain management programs, and frequent prescriptions of meloxicam for inpatient and outpatient care. Hospitals benefit from bulk procurement and formulary inclusion of meloxicam, increasing accessibility. Physicians in hospital settings prefer meloxicam for its efficacy, safety, and availability in multiple dosage forms. Hospitals also play a key role in educating patients on proper NSAID use, boosting adherence. Large-scale hospital networks in developed countries contribute to consistent demand. The presence of pharmacy departments within hospitals ensures reliable supply and monitoring.

The home healthcare segment is expected to witness the fastest growth from 2025 to 2032, driven by rising demand for convenient pain management solutions for chronic arthritis patients. Oral and dispersible meloxicam tablets are increasingly delivered through home healthcare providers and online pharmacies. Aging populations and the preference for home-based treatment support segment expansion. Digital health monitoring tools also facilitate remote adherence tracking. Government and insurance initiatives supporting home care for chronic conditions further accelerate adoption. The convenience of home-based delivery and telemedicine consultations strengthens market growth.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others. The retail pharmacy segment dominated the market in 2024, holding the largest revenue share due to easy accessibility, high consumer trust, and widespread presence in urban and semi-urban regions. Retail pharmacies provide convenient purchase options for patients requiring chronic NSAID therapy. The segment benefits from active marketing campaigns by pharmaceutical companies and physician recommendations. Retail channels also enable immediate availability of both generic and branded meloxicam. High customer footfall and repeat purchases strengthen this segment. Patient familiarity with local pharmacies enhances brand loyalty and consistent demand.

The online pharmacy segment is expected to witness the fastest growth from 2025 to 2032, driven by increasing e-commerce penetration, home delivery convenience, and growing acceptance of digital healthcare platforms. Patients, particularly in remote or underserved areas, prefer online channels for reliable access to meloxicam. Subscription-based and telemedicine-integrated services further support market expansion. For instance, online pharmacies now offer automated reminders and dosage tracking for chronic therapy management. The COVID-19 pandemic accelerated acceptance of online pharmacy services, boosting long-term adoption. Integration with digital health records enhances personalized medication delivery and adherence tracking.

Meloxicam Market Regional Analysis

• North America dominated the meloxicam market with the largest revenue share of 39% in 2024, characterized by high healthcare expenditure, widespread prescription drug usage, and a strong presence of key pharmaceutical manufacturers, with the U.S. experiencing substantial growth in both generic and branded meloxicam formulations, driven by ongoing clinical research and adoption in chronic pain management protocols
• Patients and healthcare providers in the region highly value meloxicam for its efficacy, lower gastrointestinal risk, and convenient once-daily dosing, making it a preferred choice for chronic inflammatory conditions
• This widespread adoption is further supported by well-established healthcare infrastructure, high healthcare expenditure, and strong presence of key pharmaceutical manufacturers, establishing meloxicam as a widely prescribed NSAID in both outpatient and hospital settings

U.S. Meloxicam Market Insight

The U.S. meloxicam market captured the largest revenue share of 42% in 2024 within North America, fueled by the rising prevalence of arthritis, osteoarthritis, and other musculoskeletal disorders. Patients and healthcare providers are increasingly prioritizing effective pain management and anti-inflammatory therapies, with meloxicam emerging as a preferred NSAID due to its once-daily dosing and improved gastrointestinal safety. The growing adoption of generic formulations, combined with strong insurance coverage and advanced healthcare infrastructure, further propels the meloxicam market. Moreover, ongoing clinical research, physician awareness programs, and patient adherence initiatives are significantly contributing to the market's expansion.

Europe Meloxicam Market Insight

The Europe meloxicam market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by increasing cases of chronic inflammatory conditions and the rising geriatric population. The growth of outpatient care, specialty clinics, and home healthcare services is fostering the adoption of meloxicam. European patients and physicians are drawn to its efficacy, tolerability, and availability in both branded and generic forms. The market is experiencing significant growth across hospital, specialty clinic, and retail pharmacy channels, with meloxicam being increasingly prescribed in both new treatment protocols and ongoing chronic disease management.

U.K. Meloxicam Market Insight

The U.K. meloxicam market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by heightened awareness of arthritis management and the preference for safer, long-term NSAID therapy. In addition, increasing incidence of rheumatoid arthritis and osteoarthritis is encouraging physicians to prescribe meloxicam. The UK’s robust healthcare infrastructure, prescription coverage, and well-established retail and online pharmacy networks are expected to continue to stimulate market growth. The growing trend of personalized treatment plans and patient education programs further supports adoption across outpatient and specialty care settings.

Germany Meloxicam Market Insight

The Germany meloxicam market is expected to expand at a considerable CAGR during the forecast period, fueled by rising awareness of chronic pain management and increasing healthcare expenditure. Germany’s well-developed infrastructure and focus on advanced pharmaceutical care promote meloxicam adoption, particularly in hospitals and specialty clinics. The availability of both branded and generic formulations, alongside physician preference for drugs with improved safety profiles, contributes to market growth. Integration of meloxicam into standardized arthritis and musculoskeletal treatment protocols is becoming increasingly prevalent, with a strong emphasis on long-term efficacy and patient adherence.

Asia-Pacific Meloxicam Market Insight

The Asia-Pacific meloxicam market is poised to grow at the fastest CAGR of 25% during the forecast period of 2025 to 2032, driven by increasing prevalence of arthritis, rising disposable incomes, and expansion of healthcare infrastructure in countries such as China, India, and Japan. The region's growing awareness of chronic pain management, supported by government initiatives promoting access to essential medicines, is driving the adoption of meloxicam. Furthermore, APAC’s role as a manufacturing hub for generic formulations is enhancing affordability and accessibility, expanding the patient base. The rising availability of meloxicam in hospitals, retail pharmacies, and online channels is further boosting market growth.

Japan Meloxicam Market Insight

The Japan meloxicam market is gaining momentum due to the country’s aging population, high prevalence of arthritis, and advanced healthcare system. Japanese patients and physicians emphasize safer long-term NSAID therapies, supporting meloxicam adoption. Integration of meloxicam therapy with hospital outpatient programs, home healthcare services, and specialty clinics is fueling growth. In addition, physician awareness programs and patient adherence initiatives are promoting consistent usage. The availability of both branded and generic formulations, combined with patient preference for convenient dosing, is further contributing to market expansion.

India Meloxicam Market Insight

The India meloxicam market accounted for the largest revenue share in Asia-Pacific in 2024, attributed to the country’s growing geriatric population, increasing arthritis prevalence, and expanding healthcare access. India represents one of the largest markets for NSAIDs, with meloxicam becoming increasingly preferred in hospital, retail, and online pharmacy channels. The push towards affordable healthcare, government initiatives for chronic disease management, and rising patient awareness are key factors propelling the market. In addition, the availability of cost-effective generic meloxicam formulations and strong domestic pharmaceutical manufacturing support sustained growth in India.

Meloxicam Market Share

The Meloxicam industry is primarily led by well-established companies, including:

• Boehringer Ingelheim International GmbH (Germany)
• Teva Pharmaceuticals USA, Inc. (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Amgen Inc. (U.S.)
• Novartis AG (Switzerland)
• AbbVie Inc. (U.S.)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• AstraZeneca (U.K.)
• GSK plc (U.K.)
• Eli Lilly and Company (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Bayer AG (Germany)
• Sandoz Group AG (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Hikma Pharmaceuticals PLC (Jordan)
• Pharmascience Inc. (Canada)

What are the Recent Developments in Global Meloxicam Market?

• In August 2025, Viatris presented data on MR-107A-02, a novel fast-acting meloxicam formulation, at the PAINWeek 2025 conference. The presentations included efficacy, safety, and opioid use reduction data in different surgery models, highlighting the potential of this formulation in enhancing postoperative pain management
• In July 2025, most meloxicam formulations have expired patents, leading to increased generic competition. This shift has resulted in lower prices and thinner profit margins for branded manufacturers, making meloxicam more accessible to a broader patient population
• In June 2025, Azurity Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved Xifyrm (meloxicam injection) for the management of moderate-to-severe pain in adults. This intravenous formulation offers a once-daily dosing regimen, providing a non-opioid alternative for pain management in hospital settings
• In January 2025, the FDA approved Symbravo, a combination tablet of meloxicam and rizatriptan, developed by Axsome Therapeutics. This oral medication is indicated for the acute treatment of migraines in adults, aiming to provide rapid and sustained relief from moderate to severe migraine attacks
• In August 2023, the FDA determined that ANJESO (meloxicam injection) was not withdrawn from sale for reasons of safety or effectiveness. This determination allows for the approval of abbreviated new drug applications (ANDAs) for generic versions of meloxicam injection, potentially increasing market competition and accessibility

SKU-61447